Fangsheng Pharmaceutical (603998.SH): H Model Clinical Trial Summary Report of Zhi Long Tong Luo Tablets

Financial website app news: Fangsheng Pharmaceutical (603998.SH) announced that on September 22, 2025, the company's research and development of traditional Chinese medicine innovative drug Zhi Long Tong Luo Pian obtained a phase II clinical study report. Indications: It has the effects of nourishing Qi, promoting blood circulation, dispelling blood stasis, and promoting collateral circulation. It is suitable for the treatment of sequelae of cerebral infarction (ischemic stroke) caused by meridian blockage, damage to collateral vessels and marrow, loss of sensation and movement, weakness of limbs, speech impediment, tongue deviation, fatigue, memory loss, and insomnia caused by Qi deficiency and blood stasis.